Senores Pharmaceuticals receives Philippine FDA approval for 10 products

Senores Pharmaceuticals Limited today announced that it has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for a basket of 10 products across Therapies like Cardiovascular, CNS, and Pain management, etc. This milestone marks a significant step in the company's strategy to expand its footprint in Southeast Asia and enhance access to affordable healthcare.

The approvals provide Senores Pharmaceuticals with a strong platform to serve the Philippines. The market size of these particular drugs in the Philippines is valued at US $23 million, underscoring the immense opportunity for growth and patient impact.

"These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients," said Swapnil Shah, Managing Director of Senores Pharmaceuticals. "Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as a trusted partner in advancing healthcare."

With these regulatory endorsements, strong manufacturing capabilities, Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region, leveraging its expertise, global partnerships, and uncompromising quality standards to improve treatment outcomes and broaden patient access.

Shares of Senores Pharmaceuticals Limited was last trading in BSE at Rs. 777.40 as compared to the previous close of Rs. 784.25. The total number of shares traded during the day was 8675 in over 447 trades.

The stock hit an intraday high of Rs. 790.75 and intraday low of 766.90. The net turnover during the day was Rs. 6740699.00.

Source : Equity Bulls

Keywords

SenoresPharmaceuticals SENORES INE0RB801010 Philippines FDA Approval 10Products